Effect of Regular Consumption of a Miraculin-Based Food Supplement on Taste Perception and Nutritional Status in Malnourished Cancer Patients: A Triple-Blind, Randomized, Placebo-Controlled Clinical Trial-CLINMIR Pilot Protocol.

Taste disorders are common among cancer patients undergoing chemotherapy, with a prevalence ranging from 20% to 86%, persisting throughout treatment. This condition leads to reduced food consumption, increasing the risk of malnutrition. Malnutrition is associated not only with worse treatment efficacy and poor disease prognosis but also with reduced functional status and quality of life. The fruit of Synsepalum dulcificum (Daniell), commonly known as miracle berry or miracle fruit, contains miraculin, a taste-modifying protein with profound effects on taste perception. The CLINMIR Protocol is a triple-blind, randomized, placebo-controlled clinical trial designed to evaluate the regular consumption of a food supplement containing a miraculin-based novel food, dried miracle berry (DMB), on the taste perception (measured through electrogustometry) and nutritional status (evaluated through the GLIM Criteria) of malnourished cancer patients under active antineoplastic treatment. To this end, a pilot study was designed with 30 randomized patients divided into three study arms (150 mg DMB + 150 mg freeze-dried strawberries, 300 mg DMB, or placebo) for three months. Throughout the five main visits, an exhaustive assessment of different parameters susceptible to improvement through regular consumption of the miraculin-based food supplement will be conducted, including electrical and chemical taste perception, smell perception, nutritional and morphofunctional assessment, diet, quality of life, the fatty acid profile of erythrocytes, levels of inflammatory and cancer-associated cytokines, oxidative stress, antioxidant defense system, plasma metabolomics, and saliva and stool microbiota. The primary anticipated result is that malnourished cancer patients with taste distortion who consume the miraculin-based food supplement will report an improvement in food taste perception. This improvement translates into increased food intake, thereby ameliorating their nutritional status and mitigating associated risks. Additionally, the study aims to pinpoint the optimal dosage that provides maximal benefits. The protocol adheres to the SPIRIT 2013 Statement, which provides evidence-based recommendations and is widely endorsed as an international standard for trial protocols. The clinical trial protocol has been registered at the platform for Clinical Trials (NCT05486260).

[Evaluation of the organoleptic characteristics of an oral nutritional supplement designed specifically for the cancer patient]. / Evaluación de las características organolépticas de un suplemento nutricional oral diseñado específicamente para el paciente oncológico.

Introduction: Introduction: oral nutritional supplements (ONS) are nutritional therapies used to treat malnutrition in cancer patients, therefore, innovation in these treatments, from nutrients to sensory quality, is essential to ensure their consumption. Objectives: to evaluate the organoleptic characteristic of different prototypes of oral nutritional supplements specifically designed for cancer patients. Method: cross-sectional, randomized, double-blind pilot clinical study in patients with any type of cancer, with or without oncological treatment, who tasted five ONS prototypes with different flavors (brownie, tropical, pineapple, tomato and ham) and different sensory qualities in order to evaluate their organoleptic characteristics (color, smell, taste, residual taste, texture and density) through a specific questionnaire. Results: thirty patients aged 67.5 ± 11.2 years and body mass index (BMI) of 22.3 ± 3.52 kg/m2 were evaluated. The most prevalent tumors were head and neck (30 %), pancreas (20 %) and colon (17 %); 65 % of the patients had lost ≥ 10 % of their body weight in six months. The best rated supplements by the cancer population were those with brownie flavor (23.67 ± 3.91 points) and tropical (20.33 ± 3.37 points), while the least valued were tomato (16.33 ± 5.44 points) and ham flavor (13.97 ± 4.64 points). Conclusions: cancer patients value the organoleptic characteristics of ONS with sweet flavors, such as brownie, and fruity flavors, such as tropical, much more positively. Less appreciated by these patients are those with a salty taste, such as ham and tomato flavor.

Introducción: Introducción: los suplementos nutricionales orales (SNO) son una de las terapias nutricionales más utilizadas para tratar la desnutrición en los pacientes oncológicos. Por ello, es de gran importancia contar con la innovación en estos tratamientos, desde los nutrientes hasta la calidad sensorial, para asegurar su consumo. Objetivos: evaluar las características organolépticas de diferentes prototipos de SNO diseñados específicamente para pacientes oncológicos. Métodos: estudio clínico piloto transversal, aleatorizado, cruzado y doble ciego en pacientes con cualquier tipo de cáncer, con o sin tratamiento oncológico, a los que se les realizó una cata de cinco prototipos de SNO con distintos sabores (brownie, tropical, piña, tomate y jamón) y distintas cualidades sensoriales para evaluar sus características organolépticas (color, olor, sabor, gusto residual, textura y densidad) a través de un cuestionario específico. Resultados: treinta pacientes de 67,5 ± 11,2 años y con un índice de masa corporal (IMC) de 22,3 ± 3,52 kg/m2 fueron evaluados. Los tumores más prevalentes fueron cabeza y cuello (30 %), páncreas (20 %) y colorrectal (17 %). El 65 % de los pacientes había perdido ≥ 10 % del peso corporal en seis meses. Los SNO mejor valorados fueron los sabores brownie (23,67 ± 3,91 puntos) y tropical (20,33 ± 3,37 puntos) mientras que los menos valorados fueron los SNO con sabor tomate (16,33 ± 5,44 puntos) y jamón (13,97 ± 4,64 puntos). Conclusión: los pacientes oncológicos valoran de forma mucho más positiva las características organolépticas de los SNO con sabores dulces, como el brownie, y los sabores afrutados, como el tropical. Menos apreciados por este colectivo son aquellos con un sabor salado, como el sabor jamón y tomate.

A standardized, integral nutritional intervention and physical activity program reduces body weight in women newly diagnosed with breast cancer.

INTRODUCTION: Introduction: breast cancer is the most common invasive cancer among women in developed countries. At diagnosis, approximately 70 % of women are overweight, and the additional weight gain that can result from the ensuing treatments has been associated with cancer recurrence and progression. Objectives: the main objective was to compare the effect of only a nutritional intervention (CG) with a nutrition education program (nutritional intervention, nutrition education, and physical activity) (IG) for 1 year. Methods: a total of 65 women with breast cancer who had been evaluated at the Clinical Nutrition Department, La Paz University Hospital, Madrid, Spain were recruited into 2 groups: a control group (CG) and an intervention group (IG). Results: the IG showed a significant reduction in body weight (-1.87 ± 3.41 vs. 1.48 ± 2.01 kg, p < 0.05), BMI (-0.61 ± 1.40 vs. 0.65 ± 0.88 kg/m2, p < 0.05), total cholesterol (-32.92 ± 38.45 vs. -3.23 ± 39.73 mg/dl, p < 0.05), and low-density lipoprotein cholesterol (-35.29 ± 27.50 vs. 6.33 ± 40.70 mg/dl, p < 0.05). Both groups were shown to be more conscious of the importance of physical activity, with increased consumption of grains, fruits, oily fish, and dairy. Conclusions: dietary interventions and physical activity were shown to be important to achieving several physical and physiological benefits that could reduce some risk factors associated with breast cancer recurrence and progression.

INTRODUCCIÓN: Introducción: el cáncer de mama es el cáncer invasivo más común entre las mujeres de los países desarrollados. En el momento del diagnóstico, aproximadamente el 70 % de las mujeres tienen sobrepeso, y el aumento de peso adicional que puede resultar de los tratamientos subsiguientes se ha asociado con la recurrencia y progresión de la enfermedad. Objetivos: el objetivo principal del estudio fue comparar el efecto de solo una intervención nutricional (GC) con un programa integral de educación nutricional (intervención y educación nutricional y actividad física) (IG) durante 1 año. Métodos: un total de 65 mujeres con cáncer de mama previamente evaluadas en la Unidad de Nutrición Clínica y Dietética del Hospital Universitario La Paz, Madrid, España, fueron reclutadas y divididas en 2 grupos: grupo de control (GC) y grupo de intervención (GI). Resultados: el GI mostró una reducción significativa del peso corporal (-1,87 ± 3,41 vs. 1,48 ± 2,01 kg, p < 0,05), IMC (-0,61 ± 1,40 vs. 0,65 ± 0,88 kg/m2, p < 0,05), colesterol total (-32,92 ± 38,45 vs. -3,23 ± 39,73 mg/dl, p < 0,05) y colesterol unido a lipoproteínas de baja densidad (LDL) (-35,29 ± 27,50 vs. 6,33 ± 40,70 mg/dl, p < 0,05). Al finalizar el estudio, ambos grupos fueron más conscientes de la importancia de la actividad física y demostraron consumir una cantidad más elevada de cereales, frutas, pescado azul y lácteos. Conclusiones: las intervenciones dietéticas junto con la práctica de actividad física son importantes para lograr beneficios físicos y fisiológicos que podrían reducir algunos factores de riesgo asociados con la recurrencia y progresión del cáncer de mama.

Regular Consumption of Lipigo® Promotes the Reduction of Body Weight and Improves the Rebound Effect of Obese People Undergo a Comprehensive Weight Loss Program.

Obesity is a global public health problem. OBJECTIVE: To evaluate the effect of the regular consumption of the product Lipigo® on body weight and rebound effect on overweight/obese subjects undergoing a comprehensive weight loss program. METHODS: A randomized, parallel, double-blind, placebo-controlled clinical trial was conducted with male and female subjects presenting a BMI 25-39.9 kg/m2. All subjects underwent a comprehensive weight loss program (WLP) for 12 weeks, which included an individualized hypocaloric diet, physical activity recommendations, nutritional education seminars, and three times a day consumption of the product Lipigo® or Placebo. After-WLP, subjects continued the treatment for 9 months to assess rebound effect. Body weight (BW), BMI, and body composition were measured at the beginning and the end of the WLP, and in the follow-up. RESULTS: A total of 120 subjects (85% women) 49.0 ± 9.5 years old and with a BW of 81.57 ± 13.26 kg (BMI 31.19 ± 3.44 kg/m2) were randomized and 73 subjects finished the study. At the end of the WLP, there was a tendency toward reduced BW (p = 0.093), BMI (p = 0.063), and WC (p = 0.059) in the treated group. However, subjects with obesity type 1 (OB1) from the treated group significantly reduced body weight (-5.27 ± 2.75 vs. -3.08 ± 1.73 kg; p = 0.017) and BMI (-1.99 ± 1.08 vs. -1.09 ± 0.55 kg/m2; p = 0.01) compared with placebo. They also presented a minor rebound effect after 9 months with product consumption (-4.19 ± 3.61 vs. -1.44 ± 2.51 kg; p = 0.026), minor BMI (-1.61 ± 1.43 vs. -0.52 ± 0.96 kg/m2; p = 0.025) and tended to have less fat-mass (-3.44 ± 2.46 vs. -1.44 ± 3.29 kg; p = 0.080) compared with placebo. CONCLUSIONS: The regular consumption of the product Lipigo® promotes the reduction of body weight and reduces the rebound effect of obese people after 52 weeks (12 months), mainly in obesity type 1, who undergo a comprehensive weight loss program.

A Dairy Product to Reconstitute Enriched with Bioactive Nutrients Stops Bone Loss in High-Risk Menopausal Women without Pharmacological Treatment.

Osteoporosis is a multifactorial disease characterized by the loss of bone mass and deterioration of the internal structure of the bone, increasing the risk of fractures, and is becoming an economic and social problem. The main treatment is pharmacological, however, the population demands other therapies, such as foods with nutrients beneficial to bone health. Seventy-eight healthy menopausal women at risk of osteoporosis or untreated osteopenia were recruited for a randomized, parallel, double-blind clinical trial with two intervention groups: one group consumed a serving a day of the experimental enriched product (experimental group (EG)) and the other group (control group (CG)) consumed the same product without enrichment. The main objective was to compare the effect of consuming a dairy preparation to reconstitute, similar to yogurt when prepared, enriched in calcium, vitamin D, vitamin K, vitamin C, zinc, magnesium, L-leucine and probiotic (Lactobacillus plantarum 3547) on bone metabolism markers for 24 weeks. The EG showed a significantly increased bone mass compared to the CG (0.01 ± 0.03 vs. -0.01 ± 0.03 kg; p < 0.05). In addition, the EG maintained their bone mineral density (BMD) compared to the CG, whose BMD significantly decreased at the end of the study. For biochemical markers, the EG significantly increased the serum levels of the N-terminal propeptide of type I collagen (P1NP) bone formation marker (13.19 ± 25.17 vs. -4.21 ± 15.62 ng/mL; p < 0.05), and decreased the carbo-terminal telopeptide of type I collagen (CTx) bone resorption marker compared to the CG (-0.05 ± 0.19 vs. 0.04 ± 0.14 ng/mL; p < 0.05). On the other hand, the EG exhibited a significantly decreased systolic and diastolic blood pressure compared to the start of the study. Finally, the EG significantly increased their dietary calcium and vitamin D intake compared to the CG. In conclusion, the regular consumption of a dairy product to reconstitute enriched with bioactive nutrients improves bone health markers in menopausal women at risk of osteoporosis without pharmacological treatment.

Consumption of Goat Cheese Naturally Rich in Omega-3 and Conjugated Linoleic Acid Improves the Cardiovascular and Inflammatory Biomarkers of Overweight and Obese Subjects: A Randomized Controlled Trial.

This study examines the value of a goat cheese naturally enriched in polyunsaturated fatty acids (PUFA) (n-3 PUFA and conjugated linolenic acid (CLA)) as means of improving cardiovascular and inflammatory health. Sixty-eight overweight and obese subjects (BMI ≥ 27 and <40 kg/m2), with at least two risk factors for cardiovascular disease (CVD) in a lipid panel blood tests, participated in a randomized, placebo-controlled, double-blind, parallel designed study. The subjects consumed for 12 weeks: (1) 60 g/d control goat cheese and (2) 60 g/d goat cheese naturally enriched in n-3 PUFA and CLA. Diet and physical activity were assessed. Anthropometric and dual-energy X-ray absorptiometry (DXA) tests were performed. Blood samples were collected at the beginning and at the end of the study period. Changes in health status, lifestyle and dietary habits, and daily compliance were recorded. The consumption of a PUFA-enriched goat cheese significantly increased plasma high-density lipoprotein (HDL)-cholesterol, as well as in apolipoprotein B, and it significantly decreased high-sensitivity C-reactive protein concentrations compared to the control goat cheese (p < 0.05). The significant improvement of the plasma lipid profile and inflammatory status of people with risk for CVD due to the consumption of PUFA-enriched cheese suggests a potential role of this dairy product as an alternative to develop high nutritional value food in a balanced diet comprising regular exercise.

Supplementation with Hydroxytyrosol and Punicalagin Improves Early Atherosclerosis Markers Involved in the Asymptomatic Phase of Atherosclerosis in the Adult Population: A Randomized, Placebo-Controlled, Crossover Trial.

Hydroxytyrosol (HT) and Punicalagin (PC) exert cardioprotective and anti-atherosclerotic effects. This study evaluates the effect of oral supplementation with HT and PC (SAx) on early atherosclerosis markers in middle-aged, seemingly healthy adults. A randomized, double-blinded, placebo-controlled, crossover trial was performed for 20 weeks. There were two treatment sequences (Placebo/SAx, n = 41; SAx/Placebo, n = 43) for which the intervention periods (Placebo and SAx) were 8 weeks long, followed by a 4-week wash out period. The supplement was composed of 9.9 mg of HT and 195 mg of PC, and the placebo was composed of maltodextrin. SAx increased endothelial function (Flow-mediated dilatation [FMD]: 2.36%; p < 0.001) in the endothelial dysfunction subgroup compared to the placebo (2.36 ± 3.9 vs. 0.76 ± 3.5%, p < 0.05). SAx also reduced oxLDL by -28.74 ng/mL (p < 0.05) in subjects with higher levels of oxLDL, which was an improvement compared with the placebo (-28.74 ± 40.2 vs. 25.64 ± 93.8 ng/mL, p < 0.001). The prehypertension and hypertension subgroups exhibited decreased systolic (-15.75 ± 9.9 mmHg; p < 0.001) and diastolic (-6.36 ± 8.7 mmHg; p < 0.001) blood pressure after SAx consumption. Moreover, the systolic prehypertension and hypertension subgroups presented significant differences in systolic blood pressure compared to the placebo (-15.75 ± 9.9 vs. -2.67 ± 12.0 mmHg, p < 0.05). In conclusion, the supplement exerted anti-atherosclerotic effects by improving endothelial function, blood pressure, and levels of circulating oxLDL, especially for persons in whom these parameters were altered.

[Bioactive food compounds as adjuvants to breast cancer treatment: vitamin D and omega-3]. / Compuestos bioactivos de alimentos como coadyuvantes a los tratamientos de cáncer de mama: vitamina D y omega-3.

INTRODUCTION: breast cancer (BC) is the most commonly diagnosed tumor in women and it continues to be the leading cause of cancer death in women. Quality of life decreases significantly during treatment and in the survivors. There is growing evidence linking the intake of certain foods, or their bioactive compounds, with better prognosis of the disease or improvements in physiological parameters that can increase BC patients' quality of life. But there are hardly any reviews to clarify the scientific evidence. OBJECTIVES: gathering and summarizing the available evidence on the effectiveness of the dietary compounds use as coadjuvants for BC treatment. METHOD: literature search using Pubmed to identify and analyze bioactive compounds as coadjvants for BC treatment. RESULTS: all tested compounds showed antitumor effects in vitro. Vvitamin D decrease risk of bone fracture, and marine lipids may reduce bone resorption and inflammation. CONCLUSION: there are bioactive compounds with potential to improve the quality of life of women with BC. Vitamin D a marine lipids provide a solid quality scientific evidence. Despite this, more controlled clinical trials are required to establish a direct link between the use of these compounds and the tumor progression or patient survival.

INTRODUCCIÓN: el cáncer de mama (CM) es el tumor más diagnosticado en mujeres y la primera causa de muerte por cáncer en este grupo de población. La calidad de vida disminuye durante los tratamientos, así como a largo plazo en las supervivientes. Numerosos estudios relacionan la ingesta de algunos alimentos o sus compuestos bioactivos con un mejor pronóstico de la enfermedad o mejoras en la calidad de vida de pacientes con CM, pero apenas existen revisiones que permitan aclarar la evidencia científica. OBJETIVOS: agrupar y sintetizar la evidencia disponible sobre la efectividad del empleo de compuestos bioactivos de alimentos como coadyuvantes del tratamiento del CM. MÉTODOS: revisión bibliográfica mediante sistema de búsqueda PubMed para la identificación y estudio de compuestos bioactivos con posible efecto coadyuvantes en el tratamiento de CM. RESULTADOS: todos los compuestos analizados mostraron efectos antitumorales in vitro. La vitamina D contribuye a reducir las fracturas óseas. Los lípidos marinos disminuyen la resorción ósea y la inflamación. CONCLUSIÓN: existen compuestos bioactivos con potencial terapéutico para mejorar la calidad de vida de mujeres con CM. La vitamina D y los lípidos marinos son los que presentan mayor evidencia. Sin embargo, se necesitan más ensayos clínicos controlados para confirmar una relación directa entre el empleo de estos compuestos y la evolución tumoral o la supervivencia en CM.

Revisión de la evidencia científica sobre el papel de compuestos bioactivos de alimentos como coadyuvantes a los tratamientos antineoplásicos de cáncer de mama / A review of the scientific evidence on the role of bioactive food compounds as adjuvants to antineoplasic breast cancer treatment

Fundamentos: El cáncer de mama (CM) es el tumor más diagnosticado en mujeres y, a pesar de las altas tasas de curación, sigue siendo la primera causa de muerte por cáncer en este grupo de población. La calidad de vida disminuye significativamente durante los tratamientos, así como a largo plazo en el creciente número de supervivientes. Por lo que se necesita buscar nuevos tratamientos coadyuvantes que permitan aumentar la supervivencia y/o mejorar la calidad de vida en este colectivo. Numerosos estudios relacionan la ingesta de algunos alimentos, o compuestos bioactivos derivados de alimentos, con un mejor pronóstico de la enfermedad o con mejoras en la calidad de vida de pacientes con CM. El objetivo fue agrupar y sintetizar la evidencia disponible sobre la efectividad del empleo de compuestos bioactivos de alimentos como coadyuvantes en el tratamiento de CM. Métodos: Revisión bibliográfica mediante el sistema de búsqueda PubMed para la identificación y estudio de compuestos bioactivos con posible efecto coadyuvante en el tratamiento de CM. Resultados: Todos los compuestos analizados mostraron efectos antitumorales in vitro. Las catequinas del té verde tienen cierto potencial en la disminución del riesgo cardiovascular, la vitamina D participa en la reducción de fracturas óseas, la vitamina E podría disminuir los casos de linfedema y los lípidos marinos participan en la reducción de la resorción ósea y la inflamación. Conclusiones: Existen compuestos bioactivos con potencial terapéutico para mejorar la calidad de vida de mujeres con CM. Aun así, no existe suficiente evidencia que confirme una relación directa entre el empleo de estos compuestos y la evolución tumoral o la supervivencia en CM (AU)

Background: Breast cancer (BC) is the most commonly diagnosed tumor in women and, despite the high cure rates, it continues to be the leading cause of cancer death in this group. Life quality decreases significantly during the treatment of BC and at long term in the growing number of survivors. There is a need to find new adjuvant treatments to increase survival and/or improve the life quality in these women. There is growing evidence linking the intake of certain foods, or bioactive compounds derived from foods, with better prognosis of the disease or improvements in physiological parameters that can increase BC patients’ quality of life. The aim was gathering and summarizing the available evidence on the effectiveness of the use of dietary bioactive compounds as coadjuvants for the BC treatment. Methods: Literature search using Pubmed to identify and analyze bioactive compounds that could act as coadjvants for BC treatment. Results: All tested compounds showed antitumor effects in vitro. The catechins in green tea have the potential to reduce cardiovascular risk, vitamin D lowers risk of bone fracture, vitamin E could have some effect in the reduction of lymphedema and marine lipids may reduce bone resorption and inflammation. Conclusions: There are bioactive compounds with potential to improve the quality of life of women with BC. Despite this, there is no sufficient evidence to establish a direct link between the use of these compounds and the tumor progression or patient survival (AU)

Nutrición y trastornos del sistema inmune / Nutrition and immune system disorders

Introducción: la energía y los nutrientes que obtenemos a través de la alimentación ejercen un papel importante en el desarrollo y preservación del sistema inmune, por lo que cualquier desequilibrio nutricional en el individuo afecta a su competencia e integridad. Objetivos: conocer el abordaje nutricional sobre diferentes trastornos del sistema inmune. Métodos: se ha realizado una revisión sobre los trastornos inmunológicos de mayor prevalencia en países desarrollados, las características nutricionales a los que se encuentran asociados y su abordaje nutricional. Resultados: el abordaje nutricional de los trastornos inmunológicos se ha centrado en los últimos años en los AGP-ω3 y la vitamina D. Mantener el peso corporal, evitar estados de desnutrición y catabolismo proteico, son estrategias clave del tratamiento nutricional. Este debe adecuarse a cada fase de la enfermedad, por lo que se trata de un proceso dinámico. Conclusiones: el abordaje nutricional de los trastornos inmunológicos, sobre todo en las enfermedades autoinmunes, no siempre es del todo claro, debido a los estados agudos y de remisión que presentan. La anorexia es uno de los síntomas más característicos, derivada del tratamiento farmacológico y el proceso inflamatorio. La dieta debe contener una elevada densidad en nutrientes que eviten el deterioro. El abordaje nutricional de los trastornos inmunológicos debe tener como objetivo mantener un estado óptimo de nutrición durante los periodos sintomáticos, prevenir su deterioro durante los episodios agudos y mejorarlo durante los periodos estables libres de sintomatología (AU)

Introduction: Energy and nutrients obtained through food play an important role in the development and preservation of the immune system therefore any nutritional imbalance affects its competence and integrity. Objectives: knowing the nutritional approach on different disorders of the immune system. Methods: A review has been carried out on the most prevalent immunological disorders in developed countries, the nutritional characteristics to which they are associated and their nutritional approach. Results: Nutritional treatment for immune disorders has focused in recent years on the role of PUFA-ω3 and vitamin D. Maintaining body weight, preventing malnutrition and protein catabolism are key strategies for nutritional treatment. This should be adapted to each disease stage because it is a dynamic process. Conclusions: Nutritional treatment for immunological disorders, especially in autoimmune diseases, is not always clear because they present acute and remission states. Anorexia is one of the most characteristic symptoms derived mainly from pharmacological treatment and inflammatory processes. Diet should be dense in nutrients that prevent deterioration. Nutritional treatment of immunological disorders should aim to maintain an optimal state of nutrition during symptomatic periods, prevent their deterioration during acute episodes and improve during stable periods free of symptoms (AU)

Indicaciones de diferentes tipos de fibra en distintas patologías / Fiber-type indication among different pathologies

Introducción: la fibra engloba los carbohidratos no digeridos ni absorbidos en el tubo digestivo, llegando intactos al colon. Se clasifica en soluble e insoluble, con propiedades fisiológicas distintas. La fibra se ha empleado frecuentemente para tratar y prevenir diversas patologías gastrointestinales. También se ha estudiado su papel en la fisiopatología de enfermedades como la diabetes, la dislipemia, la hipertensión arterial y la obesidad. Además se ha relacionado su consumo con la prevención de ciertos tumores, en especial del cáncer colorrectal, así como con el aumento de la excreción de nitrógeno en heces. Objetivos: analizar la evidencia del papel que la fibra puede tener en el tratamiento y prevención de distintas enfermedades, así como el tipo de fibra más adecuado en cada una. Métodos: revisión no sistemática en Medline y Pubmed, y posterior aplicación de los criterios de inclusión y exclusión. Resultados: diferentes tipos de fibra pueden ser útiles en el tratamiento de enfermedades gastrointestinales, como el estreñimiento, la diarrea, el síndrome de intestino irritable, la colitis ulcerosa en remisión o el síndrome de intestino corto. Los pacientes con diabetes, obesidad, hiperlipidemia, hipertensión y enfermedad cardiovascular también pueden beneficiarse del consumo principalmente de fibra soluble. La fibra alimentaria ha demostrado prevenir el cáncer de colon y otros tumores. En pacientes con encefalopatía hepática o insuficiencia renal, la fibra fermentable ha demostrado beneficios. Conclusiones: la fibra tiene un papel importante en la prevención y tratamiento de múltiples enfermedades; sin embargo, son necesarios más estudios de calidad para poder realizar recomendaciones más específicas (AU)

Introduction: fiber definition includes all those carbohydrates which are not digested nor absorbed in the upper gastrointestinal tract allowing them to reach the colon with no previous processing. Traditionally fiber has been classified according to their solubility into soluble and insoluble and different physiological properties have been defined for each type. The physiologic role of the fiber intake has been studied in diabetes, dyslipidemia or obesity. Fiber intake has also demonstrated to be beneficial in the prevention of many neoplastic diseases like colorectal cancer. It´s also known that fiber plays an important role in the faecal excretion of nitrogen. Aim: to evaluate the current evidence that fiber intake plays in the management and prevention of several different diseases, being able to determine, if possible, the most recommended fiber type for each clinical condition. Methods: a non-systematic review by searching the Medline and Pubmed was made and studies which met the inclusion criteria were identified and selected for analysis. Results: different fiber types can be useful for the treatment of several gastrointestinal diseases like constipation, diarrhea, irritable bowel syndrome, ulcerative colitis remission or short bowel syndrome. Patients diagnosed with diabetes, obesity, hyperlipidemia, hypertension and other cardiometabolic diseases can get a clinical improvement with soluble fiber intake. Dietary fiber has demonstrated to play a role in the prevention of colorrectal cancer and other neoplastic diseases. Patients with hepatic encephalopathy or chronic kidney disease will also benefit from fermentable fiber intake. Discussion: fiber plays an important role in the prevention and treatment of many clinical conditions. However further investigations are needed to establish specific fiber intake recommendations (AU)

Effects of milk supplementation with conjugated linoleic acidon weight control and body composition in healthy overweight people / Efecto de una suplementación láctea con ácido linoleico conjugado sobre el control de peso y la composición corporal de personas sanas con sobrepeso

Introduction: Conjugated linoleic acids (CLAs) have shown beneficial effects in weight control therapy however this relation is not clear. Objetive: The aim of the study was to examine the effects and safety of 3 g of a 1:1 mix of c9-t11 and t10-c12 on weight control and body composition in healthy overweight individuals. Methods: A prospective, placebo-controlled, randomised double-blind, parallel clinical trial lasting 24 weeks was carried out in 38 volunteers (29w, 9m) aged 30-55 years and BMI ≥ 27 -<30 kg/m2 who consumed 200 ml/day of skimmed milk with 3g of CLAs or 3g olive oil (placebo). Anthropometric, biochemical and dual x-ray absorptiometry (DXA) tests were measured. Diet and physical activity were assessed. Results: Subjects maintained their habitual dietary and exercise patterns over the study. Only CLA group showed a significant decrease in weight (74.43 ± 10.45 vs 73.54 ± 11.66 kg, p = 0.029) and waist circumference (91.45 ± 10.33 vs 90.65 ± 9.84 cm, p = 0.012) between baseline and end of the study. BMI and waist height ratio decreased (28.44 ± 1.08 vs 27.81 ± 1.43 kg/m2, p = 0.030 and 0.57 ± 0.05 vs 0.56 ± 0.04 p = 0.013 respectively) in CLA group at the end. CLA group experienced a reduction in total fat mass after 24 weeks (38.62 ± 5.02 vs 36.65 ± 5.64%, p = 0.035). No decrease was observed in Control group. HOMA index had no changes. Conclusions: The consumption of skimmed milk enriched with 3g of a 1:1 mixture of c9-t11 and t10-c12 for 24 weeks led to a decrease in body weight and total fat mass in healthy, overweight subjects who maintained habitual diets and exercise patterns. No adverse effects were observed. Registered under ClinicalTrials.gov Identifier No. NCT01503047 (AU)

Introducción: Los ácidos linoleicos conjugados (ALC) han mostrado unos efectos beneficiosos en el tratamiento del control de peso; sin embargo, esta relación no está clara. Objetivo: El propósito de este estudio fue examinar los efectos y la seguridad de 3 g de una mezcla 1:1 de c9-t11 y t10-c12 sobre el control de peso y la composición corporal en individuos sanos con sobrepeso. Métodos: Se realizó un estudio clínico prospectivo, de grupos paralelos, de distribución aleatoria, a doble ciego y con control placebo, de 24 semanas de duración, en 38 voluntarios (29 mujeres, 9 hombres) con edades de 30-55 años y un IMC ≥ 27 -< 30 kg/m2 que consumieron 200 ml/día de leche desnatada con 3 g de ALC o 3 g de aceite de oliva (placebo). Se midieron datos de antropometría, bioquímica y absorciometría dual de rayos X (DXA). Se evaluaron la dieta y la actividad física. Resultados: Los sujetos mantuvieron sus patrones habituales de dieta y ejercicio a lo largo del estudio. Sólo el grupo de ALC mostró una reducción significativa del peso (74,43 ± 10,45 vs 73,54 ± 11,66 kg, p = 0,029) y de la circunferencia de la cintura (91,45 ± 10,33 vs 90,65 ± 9,84 cm, p = 0,012) entre el periodo basal y el final del estudio. El IMC y el cociente cintura/talla disminuyeron (28,44 ± 1,08 vs 27,81 ± 1,43 kg/m2, p = 0,030 y 0,57 ± 0,05 vs 0,56 ± 0,04 p = 0,013, respectivamente) en el grupo ALC al final del estudio. El grupo ALC experimentó una reducción de la masa grasa total tras 24 semanas (38,62 ± 5,02 vs 36,65 ± 5,64 %, p = 0,035). No se observó reducción en el grupo control. El índice HOMA no experimentó cambios. Conclusiones: El consumo de leche desnatada enriquecida con 3 g de una mezcla 1:1 de c9-t11 y t10-c12 durante 24 semanas produjo un descenso del peso corporal y la masa grasa total en sujetos sanos con sobrepeso que mantuvieron sus patrones habituales de dieta y ejercicio físico. No se observaron efectos adversos. Registrado con el identificador núm. NCT01503047 en ClinicalTrials.gov (AU)

Effects of milk supplementation with conjugated linoleic acid on weight control and body composition in healthy overweight people.

INTRODUCTION: Conjugated linoleic acids (CLAs) have shown beneficial effects in weight control therapy however this relation is not clear. OBJETIVE: The aim of the study was to examine the effects and safety of 3g of a 1:1 mix of c9-t11 and t10-c12 on weight control and body composition in healthy overweight individuals. METHODS: A prospective, placebo-controlled, randomised double-blind, parallel clinical trial lasting 24 weeks was carried out in 38 volunteers (29w, 9m) aged 30-55 years and BMI ≥27-<30 kg/m2 who consumed 200 ml/day of skimmed milk with 3g of CLAs or 3g olive oil (placebo). Anthropometric, biochemical and dual x-ray absorptiometry (DXA) tests were measured. Diet and physical activity were assessed. RESULTS: Subjects maintained their habitual dietary and exercise patterns over the study. Only CLA group showed a significant decrease in weight (74.43 ± 10.45 vs 73.54 ± 11.66 kg, p = 0.029) and waist circumference (91.45 ± 10.33 vs 90.65 ± 9.84 cm, p = 0.012) between baseline and end of the study. BMI and waist height ratio decreased (28.44 ± 1.08 vs 27.81 ± 1.43 kg/m2, p = 0.030 and 0.57 ± 0.05 vs 0.56 ± 0.04 p = 0.013 respectively) in CLA group at the end. CLA group experienced a reduction in total fat mass after 24 weeks (38.62 ± 5.02 vs 36.65 ± 5.64%, p = 0.035). No decrease was observed in Control group. HOMA index had no changes. CONCLUSIONS: The consumption of skimmed milk enriched with 3g of a 1:1 mixture of c9-t11 and t10-c12 for 24 weeks led to a decrease in body weight and total fat mass in healthy, overweight subjects who maintained habitual diets and exercise patterns. No adverse effects were observed. Registered under ClinicalTrials.gov Identifier No. NCT01503047.

INTRODUCTION: Conjugated linoleic acids (CLAs) have shown beneficial effects in weight control therapy however this relation is not clear. OBJETIVE: The aim of the study was to examine the effects and safety of 3g of a 1:1 mix of c9-t11 and t10-c12 on weight control and body composition in healthy overweight individuals. METHODS: A prospective, placebo-controlled, randomised double-blind, parallel clinical trial lasting 24 weeks was carried out in 38 volunteers (29w, 9m) aged 30-55 years and BMI ¡Ý27-